Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
convalescent plasma (Mazandaran University of Medical Sciences)
- Development stage
- Unknown
- Lead developer
- Mazandaran University of Medical Sciences
- Administration
- Intravenous
01
Overview
Convalescent plasma is a biological therapy consisting of plasma collected from individuals who have recovered from COVID-19, which contains high titers of neutralizing antibodies against SARS-CoV-2. When transfused into patients with active infection, these antibodies provide immediate passive immunity by binding to the viral spike protein and preventing the virus from entering host cells. This mechanism is intended to reduce viral load, mitigate the inflammatory response, and improve clinical outcomes in severe cases. The Mazandaran University of Medical Sciences investigated this intervention in clinical trials (such as NCT04342273) to assess its efficacy in reducing mortality and improving recovery in hospitalized COVID-19 patients, particularly those admitted to intensive care units.
- Other names
- COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaCCPconvalescent plasma-Mazandaran University of Medical Sciences-COVID-19
02
Targets
RBM (SARS-CoV-2 spike receptor-binding motif)RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on convalescent plasma (Mazandaran University of Medical Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on convalescent plasma (Mazandaran University of Medical Sciences).